maxwell stanley Junior Consultant, Stephanie Marchese, has contributed to a recent publication researching treatment for Estrogen Receptor Positive Metastatic Breast Cancer.

A collaborative effort between the  and Imperial College London, Stephanie and a team of researchers have demonstrated that distinctive mutations in the Estrogen Receptor (ER) can be identified and detected through biomarkers in the blood of a breast cancer patient rather than through the current more invasive procedure of a breast biopsy. This may mean that in the future, blood tests could be used to track a treatment’s efficiency, provide a more accurate prognosis, and act as an indicator of when to switch to new drugs or interventions.

A summary of the findings can be found at: